# HALEOS LABS (NSE: HALEOSLABS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HALEOSLABS · Pivot · prices to 22 Oct 2026

HALEOS LABS (NSE: HALEOSLABS) closed at ₹1,622.00 on 22 Oct 2026, up 2.33% on the day. With a market capitalisation of ₹490 Cr, it ranks 1797th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

At its last close the stock traded at 28.3× trailing earnings, against a return on equity of 10.2% in FY25. Over the past year the share price has risen 44.8%. Its 52-week range is ₹1,091.10 (30 Jan 2026) to ₹1,774.00 (11 May 2026); the last close is 8.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹73 Cr (−11.6% year on year) and net profit ₹2 Cr (−58.0%), on a consolidated basis. Promoters held 72.11% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,622.00 |
| Market cap | ₹490 Cr |
| P/E (trailing) | 28.3 |
| ROE | 10.2% (FY25) |
| ROCE | 14.1% (FY25) |
| Debt to equity | 0.43 |
| 52-week high | ₹1,774.00 (11 May 2026) |
| 52-week low | ₹1,091.10 (30 Jan 2026) |
| 1-year return | +44.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹73 Cr | −11.6% | ₹2 Cr | −58.0% | ₹8.75 |
| Q4 FY26 | ₹75 Cr | −15.7% | ₹0 Cr | −90.2% | ₹1.44 |
| Q3 FY26 | ₹95 Cr | +12.0% | ₹7 Cr | +37.1% | ₹21.89 |
| Q2 FY26 | ₹81 Cr | +3.7% | ₹6 Cr | +94.8% | ₹20.19 |
| Q1 FY26 | ₹83 Cr | −10.9% | ₹4 Cr | −38.3% | ₹13.75 |
| Q4 FY25 | ₹89 Cr | −1.0% | ₹3 Cr | −46.2% | ₹9.83 |
| Q3 FY25 | ₹85 Cr | +17.4% | ₹5 Cr | +17.7% | ₹18.08 |
| Q2 FY25 | ₹78 Cr | +13.3% | ₹3 Cr | — | ₹15.46 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹345 Cr | ₹19 Cr |
| FY24 | ₹306 Cr | ₹6 Cr |
| FY23 | ₹316 Cr | ₹11 Cr |
| FY22 | ₹350 Cr | ₹25 Cr |
| FY21 | ₹266 Cr | ₹14 Cr |
| FY20 | ₹261 Cr | ₹10 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.11%
- Domestic institutions: 0.31%
- Non-institutions: 27.58%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Hemant Surgical](https://app.pivotnow.in/stock/HSIL) | — | ₹551 Cr | — | — |
| [Prevest Denpro](https://app.pivotnow.in/stock/PREVEST) | — | ₹472 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹780.50 | ₹445 Cr | — | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹865.50 | ₹382 Cr | 11 | — |

## Questions and answers

### What is the share price of HALEOS LABS today?

HALEOS LABS (NSE: HALEOSLABS) last closed at ₹1,622.00 on 22 Oct 2026. Its 52-week high is ₹1,774.00 and its 52-week low is ₹1,091.10.

### What is the market cap of HALEOS LABS?

HALEOS LABS's market capitalisation is ₹490 Cr (₹490 Cr) at the 22 Oct 2026 close, ranking 1797th among the NSE companies Pivot tracks.

### What is the P/E ratio of HALEOS LABS?

HALEOS LABS trades at a trailing P/E of 28.3.

### What is the ROE and ROCE of HALEOS LABS?

Return on equity was 10.2% in FY25 and return on capital employed was 14.1% in FY25 (consolidated figures).

### Is HALEOS LABS a debt-free company?

No. HALEOS LABS's debt-to-equity ratio was 0.43 in FY25, with total debt of ₹18 Cr.

### What were HALEOS LABS's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), HALEOS LABS reported revenue of ₹73 Cr, −11.6% year on year, and net profit of ₹2 Cr, −58.0% year on year.

### How has HALEOS LABS stock performed over the last year?

HALEOS LABS's share price has risen 44.8% over the past year, +4.7% over three months and +9.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of HALEOS LABS?

As of 30 Jun 2026: promoters 72.11%, domestic institutions 0.31%, non-institutions 27.58%.

### Who are HALEOS LABS's competitors?

The listed Pharma & Healthcare companies closest to HALEOS LABS by market cap are Hemant Surgical, Prevest Denpro, Asarfi Hospital, Albert David, Transchem and Jenburkt Pharma.

### Is HALEOS LABS a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out HALEOS LABS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HALEOSLABS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.